Arribas[14], Caraco[6], Fischer[7], Painter[9] Arribas[14], Caraco[6], Fischer[7], Painter[9] Arribas[14], Caraco[6], Fischer[7], Painter[9] Arribas[14], Caraco[6], Fischer[7], Painter[9] 200 mg 200 mg 200 mg 200 mg
Outcome No. of participants (studies) Effect estimate (95% CI) Risk of bias Inconsistency Indirectness Imprecision Publication bias
A.Virological Profile 1.SARS-COV-2 RNA ERROR RATE
150
MD 1.27 [-0.32, 2.86]
Low
Low
Not Serious
Serious
N/A
2. Time for clearance SARS-COV-2 or undetectable SARS-COV-2 in the nasopharyngeal sample 590 OD 1.33 [0.80, 2.20 Low Low Not Serious Serious N/A
3. Mean change in SARS-COV-2 from baseline in nasopharyngeal sample 382 MD -0.07 [-0.32, 0.17] Low Low Not Serious Not Serious N/A
B. Mortality 381 RR 1.74 [0.48, 6.30] Low Low Not Serious Serious N/A